Compare Firy Inc. (FIRY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Sanofi SA — how do they compare? Firy Inc. trades at $11.9 (market cap $199.80M), while Sanofi SA trades at $40.27 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 476.4× Firy Inc.'s market cap, and Sanofi SA pays a 6.01% dividend while Firy Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and Sanofi SA for 94 Days on average.
| FIRY | SNY | |
|---|---|---|
Market Cap | $199.80M | $95.18B |
Volume | 92,993 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $13.10 | $52.34 |
52-Week Low | $2.28 | $39.51 |
Typical Hold Time | 13 Days | 94 Days |
Enterprise Value | $168.40M | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY (formerly Skillz Inc.) trades at $11.85, down 5.05% today, with a bullish technical signal from moving averages despite negative fundamental metrics. The company reported Q2 2026 revenue of $31.0 million but missed EPS expectations with a net loss. Recent developments include a $719 million legal victory against Papaya Gaming and the appointment of Marc Lasry to the board, though cash burn remains elevated at -$86.41M for 2025.
The outlook remains challenged by persistent losses and negative margins, but potential collection of the legal judgment could provide significant upside. Risks include execution on cost controls and uncertainty around Papaya Gaming debt settlement. Analyst sentiment is mixed with 20% buy ratings amid high volatility.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
